Microspheres: Design and Manufacturing

Injectable Dispersed Systems: Formulation, Processing, and Performance

Volumn , Issue , 2005, Pages 305-353

  Burgess, Diane J ^a   Hickey, Anthony J ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646710558     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780849350610-13     Document Type: Chapter

References (141)

1. Burgess DJ, Hickey AJ. Microsphere technology and applications. In: Swarbrick J, Boylan J, eds. Encyclopedia of Pharmaceutical Technolog. Vol. 10. New York, NY: Marcel Dekker, 1994:1-29.
2. Rohollah S, Bruskewitz RC, Gittleman MC, Graham SD, Hudson PB, Stein B. Leuprolide acetate 22.5mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 1996; 18:647-657.
3. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997; 28:43-70.
4. Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Shrestha RD, Okui K, Morimoto Y, Terao K. Effects of intra-arterially infused biodegradable microspheres containing Mitomycin C. Cancer 1985; 55(3):522-526.
5. Gupta PK, Hung CT, Perrier DG. Albumin microspheres. I. Release characteristics of adriamycin. Int J Pharm 1986; 33:137-146.
6. Gupta PK, Hung CT, Perrier DG. Albumin microspheres. II. Effect of stabilization temperature on the release of adriamycin. Int J Pharm 1986; 33:147-153.
7. Gupta PK, Lam FC, Hung CT. Albumin microspheres. IV. Effect of protein concentration and stabilization time on the release rate of adriamycin. Int J. Pharm 1989; 51:253-258.
8. Jones C, Burton MA, Gray BN. Albumin microspheres as vehicles for the sustained and controlled release of doxorubicin. J Pharm Pharmacol 1989; 41:813-816.
9. Schwope AD, Wise DL, Howes JF. Lactic/glycolic acid polymers as narcotic antagonist delivery system. Life Sci 1968; 17:1877-1886.
10. Gardner DL, Patanus AJ, Fink DJ. Steroid release from microcapsules. In: Drug Delivery Systems. Gabelnick HL, ed. DHEW Pub. No. (NIH), 77-1238. Washington, DC:Department of Health, Education and Welfare, 1977:265-278.
11. Tsung M, Burgess DJ. Preparation and stabilization of heparin/gelatin complex coacervate microcapsules. J Pharm Sci 1997; 86:603-607.
12. Tsung M, Burgess DJ. Preparation and characterization of gelatin surface modified PLGA microspheres. AAPS PharmSci 2001; 3[2]:E11.
13. Schmidt C, Wenz R, Nies B, Moll F. Antibiotic in vivo/in vitro release, histocompatibility and biodegradation of gentamicin implants based on lactic acid polymers and copolymers. J Control Release 1995; 37:83-94.
14. Burgess DJ, Davis SS. Potential use of albumin microspheres as a drug delivery system. II. In vivo deposition and release of steroids. Int J Pharm 1988; 46:69-76.
15. Pavanetto F, Genta I, Giunchedi P, Conti B, Conte U. Spraydried albumin microspheres for the intra-articular delivery of dexamethasone. J Microencapsul 1994; 4:445-454.
16. Firsov AA, Nazarov AD, Fomina IP. Biodegradable implants containing gentamicin: drug release and pharmacokinetics. Drug Dev Ind Pharm 1987; 13:1651-1674.
17. Narayani R, Rao KP. Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J Microencapsul 1994; 11:69-77.
18. Slobbe L, Medlicott N, Lockhart E, Davies N, Tucker I, Razzak M, Buchan G. A prolonged immune response to antigen delivered in poly (e-caprolactone) microparticles. Immunol Cell Biol 2003; 81(3):185-191.
19. Hanes J, Dawson M, Har-el Y-el, Suh J, Fiegel J. Gene delivery to the lung. In: Hickey AJ, eds. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, Inc., 2003:489-539.
20. Kim TK, Burgess DJ. unpublished results.
21. Payne RG, McGonigle JS, Yaszemski MJ, Yasko AW, Mikos AG. Development of an injectable, in situ crosslinkable, degradable polymeric carrier for osteogenic cell populations. Part 3. Proliferation and differentiation of encapsulated marrow stromal osteoblasts cultured on crosslinking poly(- propylene fumarate). Biomaterials 2002; 23(22):4381-4387.
22. Payne RG, McGonigle JS, Yaszemski MJ, Yasko AW, Mikos AG. Development of an injectable, in situ crosslinkable, degradable polymeric carrier for osteogenic cell populations. Part 2. Viability of encapsulated marrow stromal osteoblasts cultured on crosslinking poly(propylene fumarate). Biomaterials 2002; 23(22):4373-4380.
23. Payne RG, Yaszemski MJ, Yasko AW, Mikos AG. Development of an injectable, in situ crosslinkable, degradable polymeric carrier for osteogenic cell populations. Part 1. Encapsulation of marrow stromal osteoblasts in surface crosslinked gelatin microparticles. Biomaterials 2002; 23(22):4359-4371.
24. Kwok KK, Groves MJ, Burgess DJ. Production of 5-15 mm diameter alginate-polylysine microcapsules by an air-atomization technique. Pharm Res 1991; 8(3):341-344.
25. Abraham SM, Vieth RF, Burgess DJ. Novel technology for the preparation of sterile alginate-poly-l-lysine microcapsules in a bioreactor. Pharm Dev Technol 1996; 1(1):63-68.
26. Schroeder HG, Bivins BA, Sherman GP, DeLuca PP. Physiological effects of subvisible microspheres administered intravenously to beagle dogs. J Pharm Sci 1978; 67(4):C18-C23.
27. Martin A. Physical Pharmacy. 4th ed. Philadelphia: Lea and Febiger, 1993:324-361.
28. Fujiwara K, Hayakawa K, Nagata Y, Hiraoka M, Nakamura T, Shimizu Y, Ikada Y. Experimental embolization of rabbit renal arteries to compare the effects of poly L-lactic acid microspheres with and without epirubicin release against intraarterial injection of epirubicin. Cardiovasc Interv Radiol 2000; 23:218-223.
29. Hariharan M, Price JC. Solvent, emulsifier and drug concentration factors in poly(D, L-lactic acid) microspheres containing hexamethylmelamine. J Microencapsul 2002; 19(1):95-109.
30. Kobayashi D, Tsubuku S, Yamanaka H, Asano M, Miyajima M, Yoshida M. In vivo characteristics of injectable poly(DL-lactic acid) microspheres for long-acting drug delivery. Drug Dev Ind Pharm 1998; 24:819-825.
31. Coombes AG, Major D, Wood JM, Hockley DJ, Minor PD, Davis SS. Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. Biomaterials 1998; 19:1073-1081.
32. Ciftci K, Hincal AA, Kas HS, Ercan TM, Sungur A, Guven O, Ruacan S. Solid tumor chemotherapy and in vivo distribution of fluorouracil following administration in poly(L-lactic acid) microspheres. Pharm Dev Technol 1997; 2:151-160.
33. Kuang L, Yang DJ, Inoue T, Liu WC, Wallace S, Wright KC. Percutaneous intratumoral injection of cisplatin microspheres in tumor-bearing rats to diminish acute nephrotoxicity. Anticancer Drugs 1996; 7:220-227.
34. Johansen P, Tamber H, Merkle HP, Gander B. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. Eur J Pharm Biopharm 1999; 47(3):193-201.
35. Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of differ- ent immunization protocol and adjuvants. Int J Pharm 2002; 245(1-2):109-121.
36. Miller JA, Oehler DD, Pound JM. Delivery of ivermectin by injectable microspheres. J Econ Entomol 1998; 91:655-659.
37. Chowdhury DK, Mitra AK. Kinetics of a model nucleoside (guanosine) release from biodegradable poly(DL-lactideco- glycolide) microspheres: a delivery system for long-term intraocular delivery. Pharm Dev Technol 2000; 5:279-285.
38. Lunsford L, McKeever U, Eckstein V, Hedley ML. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target 2000; 8:39-50.
39. Barrio GGd, Novo FJ, Irache JM. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties. J Control Release 2003; 86(1):123-130.
40. Chen W, Lu DR. Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization. J Microencapsul 1999; 16:551-563.
41. Goldberg SN, Walovitch RC, Straub JA, Shore MT, Gazelle GS. Radiofrequency-induced coagulation necrosis in rabbits:immediate detection at US with a synthetic microsphere contrast agent. Radiology 1999; 213:438-444.
42. Hilbert AK, Fritzsche U, Kissel T. Biodegradable microspheres containing influenza A vaccine: immune response in mice. Vaccine 1999; 17:1065-1073.
43. Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, Eastman DJ, Vennari JC, Wrin T, Berman P, Murthy KK, Powell MF. Development of single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. J Pharm Sci 1998; 87:1489-1495.
44. Atkins TW. Fabrication of microspheres using blends of poly (ethylene adipate) and poly(ethylene adipate)/poly(hydroxy butyrate-hydroxyvalerate) with poly(caprolactone): incor- poration and release of bovine serum albumin. J Biomater Sci Polym Ed 1997; 8:833-845.
45. Blanco MD, Bernardo MV, Sastre RL, Olmo R, Muniz E, Teijon JM. Preparation of bupivacaine-loaded poly(vepsiln.- caprolactone) microspheres by spray drying: drug release studies and biocompatibility. Eur J Pharm Biopharm 2003; 55(2):229-236.
46. Sinisterra RD, Shastri VP, Najjar R, Langer R. Encapsulation and release of rhodium (II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres. J Pharm Sci 1999; 88:574-576.
47. Chiba M, Hanes J, Langer R. Controlled protein delivery from biodegradable tyrosine-containing poly(anhydrideco- imide) microspheres. Biomaterials 1997; 18:893-901.
48. Tokumitsu H, Ichikawa H, Fokumori Y, Block LH. Preparation of gadopentetic acid-loaded chitosan microparticles for gadolinium neutron-capture therapy of cancer by a novel emulsion-droplet coalescence technique. Chem Pharm Bull 1999; 47:838-842.
49. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progesterone- loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J Control Release 1998; 52:17-24.
50. Mi FL, Wong TB, Shyu SS. Sustained-release of oxytetracycline from chitosan microspheres prepared by interfacial acylation and spray hardening methods. J Microencapsul 1997; 14:577-591.
51. Patashnik S, Rabinovich L, Colomb G. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J Drug Target 1997; 4:371-380.
52. Elcin YM, Dixit V, Gitnick G. Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis: in vitro and in vivo studies. Artif Cells Blood Substit Immobil Biotechnol 1996; 24:257-271.
53. Tabata Y, Hijikata S, Muniruzzaman M, Ikada Y. Neovascularization effect of biodegradable gelatin microspheres incor- porating basic fibroblast growth factor. J Biomater Sci 1999; 10:79-94.
54. Laurent A, Beaujeux R, Wassef M, Rufenacht D, Boschetti E, Merland JJ. Trisacryl gelatin microspheres for therapeutic embolization, I: development and in vitro evaluation. Am J Neuroradiol 1996; 17:533-540.
55. Nakaoka R, Tabata Y, Ikada Y. Potentiality of gelatin microsphere as immunological adjuvant. Vaccine 1995; 13:653-661.
56. Brown KE, Leong K, Huang CH, Dalal R, Green GD, Haimes HB, Jimenez P, Bathon J. Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum 1998; 41:2185-2195.
57. Yoshikawa Y, Komuta Y, Nishihara T, Itoh Y, Yoshikawa H, Takada K. Preparation and evaluation of once-a-day injectable microspheres of interferon alpha in rats. J Drug Target 1999; 6:449-461.
58. Nehra A, Gettman MT, Nugent M, Bostwick DG, Barrett DM, Goldstein I, Krane RJ, Moreland RB. Transforming growth factor-beta 1 (TGF-beta 1) is sufficient to induce fibrosis of rabbit corpus cavernosum in vivo. J Urol 1999; 162:910-915.
59. Leblond FA, Simard G, Henley N, Rocheleau B, Huet PM, Halle JP. Studies on smaller (approximately 315 mM) microcapsules:IV Feasibility and safety of intrahepatic implantations of small alginate poly-L-lysine microcapsules. Cell Transplant 1999; 8:327-337.
60. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target 1998; 6:215-227.
61. Huang LK, Mehta RC, DeLuca PP. Evaluation of a statistical model for the formation of poly [acryloyl hydroxyethyl starch] microspheres. Pharm Res 1997; 14:475-482.
62. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm Res 2003; 20(3):452-459.
63. Habler O, Kleen M, Hutter J, Podtschaske A, Tiede M, Kemming G, Corso C, Batra S, Keipert P, Faithfull S, Mess- mer K. Effects of hemodilution on splanchnic perfusion and hepatorenal function. II. Renal perfusion and hepatorenal function. Eur J Med Res 1997; 2:419-424.
64. Conway BR, Eyles JE, Alpar HO. A comparative study on the immune responses to antigens in PLA and PHB microspheres. J Control Release 1997; 49:1-9.
65. Jeffery H, Davis SS, O’Hagan DT. The preparation and characterization of poly(lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation. Int J Pharm 1991; 77:169-175.
66. Bodmer D, Kissel T, Traechslin E. Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. J Control Release 1992; 21:129-138.
67. Zhang Y, Zale S, Sawyer L, Bernstein H. Effect of salts on poly(DL-lactide-co-glycolide) polymer hydrolysis. J Biomed Mater Res 1997; 34:531-538.
68. Dilova V, Shishkova V. Albumin microspheres as a drug delivery system for dexamethasone: pharmaceutical and pharmacokinetic aspects. J Pharm Pharmacol 1993; 45:987-989.
69. Kim HC, Burgess DJ. Effect of drug stability an analysis of release data from controlled release Microspheres. J Microencapsulation 2002; 19(5):631-640.
70. Kim TK, Burgess DJ. Formulation and release characteristics of poly(lactic-co-glycolic acid) microspheres containing chemically modified protein. J Pharm Pharmacol 2001; 53(1):23-31.
71. Benoit JP, Machais H, Rolland H, Velde VV. Biodegradable microspheres: advance in production technology. In: Benita S, ed. Microencapsulation: Methods and Industrial Applications. New York: Marcel Dekker, 1996:35-72.
72. O’Donnell PB, McGinity JW. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev 1997; 28:25-42.
73. Cao X, Shoichet MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 1999; 20:329-339.
74. Takada S, Kurokawa T, Miyazaki K, Iwasa S, Oqawa Y. Utilization of an amorphous form water-soluble GPIIb/ IIIa antagonist for controlled release from biodegradable microspheres. Pharm Res 1997; 14:1146-1150.
75. Nihant N, Schugens C, Grandfils C, Jerome R, Teyssie P. Polylactide microparticles prepared by double emulsion/ evaporation technique. I. Effect of primary emulsion stability. Pharm Res 1994; 11:1479-1486.
76. Zambaux MF, Bonneaux F, Gref R, Miaincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 1998; 50:31-40.
77. Heya T, Okada H, Tanigawara Y, Ogawa Y, Toguchi H. Effects of counterion of TRH and loading amount on control of TRH release from copoly(DL-lactic/glycolic acid) microspheres prepared by an in-water drying method. Int J Pharm 1991; 69:69-75.
78. Ghaderi R, Sturesson C, Carlfors J. Effect of preparative parameters on the characteristics of poly(D, L-Lactide-coglycolide) microspheres made by the double emulsion methods. Int J Pharm 1996; 141:205-216.
79. Cole ML, Whateley TL. Release rate profiles of theophylline and insulin from stable multiple w/o/w emulsions. J Control Release 1997; 49:51-58.
80. Sah H. A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres. J Pharm Sci 1997; 86:1315-1318.
81. Esposito E, Cortesi R, Cervellati F, Menegatti E, Nastruzzi C. Biodegradable microparticles for sustained delivery of tetracycline to the periodontal pocket: formulatory and drug release studies. J Microencapsul 1997; 14:175-187.
82. Allen T. Particle Size Measurement. 4th ed. London: Chapman and Hall, 1990:503-538.
83. Shaw DJ. Introduction to Colloid and Surface Chemistry. 3rd ed. London: Butterworths, 1986:108-126.
84. Redmon MP, Hickey AJ, DeLuca PP. Prednisolone-21-acetate poly(glycolic acid) microspheres: influence of matrix characteristics on release. J Control Release 1989; 9:99-109.
85. Kwok KK, Burgess DJ. A novel method of determination of sterility of microcapsules and measurement of viability of encapsulated organisms. Pharm Res 1992; 9(3):410-413.
86. DeLuca PP, Hickey AJ, Hazraty AM, Wedlund P, Rypacek F, Kanke M. Porous biodegradable microspheres for parenteral administration. In: Breimer DD, Speiser P, eds. Topics in Pharmaceutical Sciences. Amsterdam: Elsevier Science Publishers B.V (Biomedical Division), 1987:429-442.
87. Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 1998; 17:55-75.
88. Illum L, Davies SS, Muller RH, Mak E, West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-poloxamine 908. Life Sci 1987; 40:367-374.
89. Ghassabian S, Ehteezazi T, Forutan SM, Mortazavi SA. Dexamethasone-loaded magnetic albumin microspheres: preparation and in vitro release. Int J Pharm 1996; 130:49-55.
90. Newman KD, Sosnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by Poly(D, L-lactic-co-glycolic acid) microspheres induces type 1T helper immune responses. J Pharm Sci 1998; 87:1421-1427.
91. McCabe WL, Smith JC, Harriott P. Unit Operations of Chemical Engineering. New York: McGraw Hill, 1993.
92. Hickey AJ, Ganderton D. Pharmaceutical Process Engineering. Vol. 112. New York, NY: Marcel Dekker, 2001.
93. Bodmeier R, Wang J, Bhagwatwar H. Process and formulation variables in the preparation of wax microparticles by a melt dispersion technique. II. W/O/W multiple emulsion technique for water-soluble drugs. J Microencapsul 1992; 9:9-107.
94. Benita S, Zonai O, Benoit J-P. 5-Fluorouracil:carnauba wax microspheres for chemoembolization: an in vitro evaluation. J Pharm Sci 1986; 75:847-851.
95. Hickey AJ, Fults KA, Pillai RS. Use of particle morphology to influence the delivery of drugs from dry powder aerosols. J Biopharm Sci 1992; 3(1-2):107-113.
96. Pillai RS, Yeates DB, Miller IF, Hickey AJ. Drug release from condensation coated inhalation aerosols. Proc Int Symp Control Release Bioact Mater 1992; 19:224-225.
97. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res 1985; 19:945-955.
98. Mathiowitz E, Langer R. Polyanhydride microspheres as drug carriers I. Hot-melt microencapsulation. J Control Release 1987; 5:13-22.
99. Wurster DE. Air-suspension techniques of coating drug particles:a preliminary report. J Am Pharm Assoc Sci Ed 1959; 48:451-454.
100. Robinson MJ, Grass GM, Lantz RJ. An apparatus and method for coating of solid particles. J Pharm Sci 1968; 57:1983-1988.
101. Porter SC. Aqueous film coating: an overview. Pharm Tech 1979; 3:54-59.
102. Porter SC. The effect of additives on the properties of an aqueous film coating. Pharm Tech 1980; 4:66-75.
103. Banker GS. The new, water-based colloidal dispersions. Pharm Tech 1981; 5:54-61.
104. Lehmann K. Fluid-bed spray coating. In: Donbrow M, ed. Microcapsules and Nanoparticles in Medicine and Pharmacy. London: CRC Press, 1991:73-97.
105. Bungenberg de Jong HG. Reversible systems. In: Kruyt HG, ed. Colloid Science. Vol. II. New York: Elsevier, 1949:335-432.
106. Burgess DJ. Practical analysis of complex coacervate systems. J Colloid Interface Sci 1990; 140:227-238.
107. Burgess DJ, Davis SS, Tomlinson E. Potential use of albumin microspheres as a drug delivery system. I. Preparation and in vitro release of steroids. Int J Pharm 1987; 39:129-136.
108. Nixon JR, Microencapsulation. New York: MarcelDekker, 1976.
109. Nixon JR, Nouh A. The effect of microcapsule size on the oxidative decomposition of core materials. J Pharm Pharmacol 1978; 30:533-537.
110. Madan PL. Microencapsulation, 1. Phase separation or coacervation. Drug Dev Ind Pharm 1978; 4:95-116.
111. Burgess DJ, Carless JE. Microelectrophoretic studies of gelatin and acacia for the prediction of complex coacervation. J Colloid Interface Sci 1984; 98:1-8.
112. Jizomoto H. Phase separation induced in gelatin-base coacervation systems by addition of water-soluble nonionic polymers I: microencapsulation. J Pharm Sci 1984; 73:879-882.
113. Jizomoto H. Phase separation induced in gelatin-base coacervation systems by addition of water-soluble nonionic polymers II: Effect of molecular weight. J Pharm Sci 1985; 74:469-472.
114. Burgess DJ, Singh ON. Spontaneous formation of small sized albumin/acacia coacervate microcapsules. J Pharm Pharmacol 1993; 45:586-591.
115. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980; 210:908-910.
116. Rha CK, Rodrigues-Sanches D. U.S. Pat. 4, 749, 620, 1980.
117. Sacchetti M, Oort MMV. Spray-drying and supercritical fluid particle generation techniques. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therap. Vol. 94. New York: Marcel Dekker, 1996:337-384.
118. Wan LSC, Heng PWS, Chia CGH. Plasticizers and their effects on the microencapsulation process by spray-drying in an aqueous system. J Microencapsul 1992; 9:53-62.
119. Lam XM, Duenas ET, Cleland JL. Encapsulation and stabilization of nerve growth factor into poly(lactic-co-glycolic) acid microspheres. J Pharm Sci 2001; 90(9):1356-1365.
120. Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release 2000; 67(2-3):281-292.
121. Maa Y-F, Nguyen P-A. Method of spray freeze drying proteins for pharmaceutical administration. US 6284282, 2001.
122. Wang J, Chua KM, Wang C-H. Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres. J Colloid Interface Sci 2004; 271(1):92-101.
123. Hickey AJ, Tian Y, Parasrampuria D, Kanke M. Biliary elimination of bromsulphthalein, phenolphthalein and doxorubicin released from microspheres following intravenous administration. Biopharm Drug Dispos 1993; 14:181-186.
124. Sato T, Kanke M, Schroeder HG, DeLuca PP. Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques. Pharm Res 1988; 5:21-30.
125. Caliceti P, Elvassore N, Bertucco A. Preparation of insulin loaded polylactide microparticles by supercritical anti-solvent technique. Proc Int Symp Control Release Bioact Mater 2000; 1094-1095.
126. Ribeiro D, Santos I, Richard J, Thies C, Pech B, Benoit J-P. A supercritical fluid-based coating technology. 3: Preparation and characterization of bovine serum albumin particles coated with lipids. J Microencapsul 2003; 20(1):110-128.
127. York P, Hanna M, Shekunov BY, Humphreys GO. Microfine particle formation by SEDS (solution enhanced dispersion by supercritical fluids): scale up by design. Respir Drug Deliv 1998; VI:169-175.
128. Clark MR, DeSimone JM. Cationic polymerization of vinyl and cyclic ethers in supercritical and liquid carbon dioxide. Macromolecules 1995; 28(8):3002-3004.
129. Romack TJ, Combes JR, DeSimone JM. Free-radical telomerization of tetrafluoroethylene in supercritical carbon dioxide. Macromolecules 1995; 28(5):1724-1726.
130. Romack TJ, Maury EE, DeSimone JM. Precipitation polymerization of acrylic acid in supercritical carbon dioxide. Macromolecules 1995; 28(4):912-915.
131. McClain JB, Londono D, Combes JR, Romack TJ, Canelas DA, Betts DE, Wignall GD, Samulski ET, DeSimone JM. Solution properties of a CO2-soluble fluoropolymer via small angle neutron scattering. J Am Chem Soc 1996; 118(4):917-918.
132. Box GEP, Hunter WG, Hunter JS. Statistics for Experiments:An Introduction to Design, Data Analysis, and Model Building. New York: John Wiley and Sons, 1978.
133. Felder CB, Blanco-Prieto MJ, Heizmann J, Merkle HP, Gander B. Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters. J Microencapsul 2003; 20(5):553-567.
134. Burgess DJ, Crommelin DJA, Hussain AS, Chen M-L. Assuring quality and performance of sustained and controlled release parenterals. Eur J Pharm Sci 2004; 21(5):679-690.
135. Kim T-K, Burgess DJ. Formulation and release characteristics of poly(lactic-co-glycolic acid) microspheres containing chemically modified protein. J Pharm Pharmacol 2001; 53(1):23-31.
136. Patil SD, Burgess DJ, Papadimitrikapoulos F. Dexamethasone- loaded PLGA microspheres/PVA hydrogel composites for inflammation control. Diabet Technol Ther 2004; 6(6):887-897.
137. Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/ PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 2002; 23(7):1649-1656.
138. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res 2002; 61(2):180-187.
139. Kim TK, Burgess DJ. Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J Pharm Pharmacol 2002; 54(7):897-905.
140. Montanari L, Cilurzo F, Selmin F, Conti B, Genta I, Poletti G, Orsini F, Valvo L. Poly(lactide-co-glycolide) microspheres containing bupivacaine: comparison between gamma and beta irradiation effects. J Control Release 2003; 90(3):281-290.
141. Bittner B, Mader K, Kroll C, Borchert H-H, Kissel T. Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of g-irradiation on radical formation and polymer degradation. J Control Release 1999; 59(1):23-32.